Compare · CORT vs JNJ
CORT vs JNJ
Side-by-side comparison of Corcept Therapeutics Incorporated (CORT) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CORT and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $648.55B, about 52.6x CORT ($12.32B).
- CORT has been more active in the news (15 items in the past 4 weeks vs 8 for JNJ).
- JNJ has more recent analyst coverage (25 ratings vs 17 for CORT).
- Company
- Corcept Therapeutics Incorporated
- Johnson & Johnson
- Price
- -
- -
- Market cap
- $12.32B
- $648.55B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2004
- News (4w)
- 15
- 8
- Recent ratings
- 17
- 25
Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with serous ovarian tumors, as well as in Phase III clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator combined with Xtandi that is in open label dose finding trial to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest CORT
- Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600
- Chief Development Officer Guyer William was granted 328 shares, increasing direct ownership by 8% to 4,313 units (SEC Form 4)
- Officer Maduck Sean covered exercise/tax liability with 117 shares, exercised 25,000 shares at a strike of $8.27, sold $2,860,737 worth of shares (25,000 units at $114.43) as part of a pre-agreed trading plan and was granted 300 shares, increasing direct ownership by 2% to 9,938 units (SEC Form 4) (for withholding tax)
- Chief Financial Officer Mokari Atabak covered exercise/tax liability with 102 shares and was granted 276 shares, increasing direct ownership by 1% to 16,304 units (SEC Form 4) (withholding obligation)
- Chief Business Officer Robb Gary Charles was granted 328 shares and covered exercise/tax liability with 91 shares, increasing direct ownership by 2% to 13,663 units (SEC Form 4) to satisfy withholding obligation
- President, Oncology Vieira Roberto Wandenkolk was granted 276 shares, covered exercise/tax liability with 102 shares, exercised 58,333 shares at a strike of $21.63 and sold $6,460,766 worth of shares (58,333 units at $110.76) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 4,242 units (SEC Form 4) to cover withholding tax
- Officer Lyon Joseph Douglas was granted 260 shares and covered exercise/tax liability with 72 shares, increasing direct ownership by 3% to 5,683 units (SEC Form 4) to cover taxes
- New insider Vieira Roberto Wandenkolk claimed ownership of 4,068 shares (SEC Form 3)
- Director Park Kimberly exercised 30,000 shares at a strike of $13.49, covered exercise/tax liability with 3,315 shares and sold $3,270,169 worth of shares (26,685 units at $122.55) (SEC Form 4)
- Officer Maduck Sean exercised 30,955 shares at a strike of $11.35 and sold $3,887,320 worth of shares (30,955 units at $125.58) as part of a pre-agreed trading plan (SEC Form 4)
Latest JNJ
- Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026
- EVP, WW Chair, MedTech Schmid Timothy exercised 33,597 shares at a strike of $144.99 and sold $9,230,440 worth of shares (33,597 units at $274.74) (SEC Form 4)
- Johnson & Johnson to Participate in the Deutsche Bank 2026 Healthcare Summit
- UBS resumed coverage on Johnson & Johnson with a new price target
- New insider Cavanaugh Thomas claimed ownership of 499 shares (SEC Form 3)
- Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
- FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients
- EVP, WWC. Innovative Medicine Taubert Jennifer L exercised 15,000 shares at a strike of $115.67 and sold $3,950,400 worth of shares (15,000 units at $263.36) (SEC Form 4)
- CEO and Chairman of the Board Duato Joaquin exercised 123,291 shares at a strike of $115.67 and sold $32,199,927 worth of shares (123,291 units at $261.17) (SEC Form 4)
- Johnson & Johnson to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference